Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

Tetsuya Matsumoto Department of Microbiology, Tokyo Medical University, Tokyo, Japan Abstract: Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Matsumoto T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/a12cb9adffc44504ab76c3ce0a987e13
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a12cb9adffc44504ab76c3ce0a987e13
record_format	dspace
spelling	oai:doaj.org-article:a12cb9adffc44504ab76c3ce0a987e132021-12-02T04:03:54ZArbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens1179-1438https://doaj.org/article/a12cb9adffc44504ab76c3ce0a987e132014-09-01T00:00:00Zhttp://www.dovepress.com/arbekacin-another-novel-agent-for-treating-infections-due-to-methicill-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438 Tetsuya Matsumoto Department of Microbiology, Tokyo Medical University, Tokyo, Japan Abstract: Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams. Keywords: synergistic effect, Habekacin, MRSA, multidrug-resistant Gram-negative bacteriaMatsumoto TDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2014, Iss default, Pp 139-148 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Matsumoto T Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
description	Tetsuya Matsumoto Department of Microbiology, Tokyo Medical University, Tokyo, Japan Abstract: Arbekacin sulfate (ABK), an aminoglycoside antibiotic, was discovered in 1972 and was derived from dibekacin to stabilize many common aminoglycoside modifying enzymes. ABK shows broad antimicrobial activities against not only Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) but also Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. ABK has been approved as an injectable formulation in Japan since 1990, under the trade name Habekacin, for the treatment of patients with pneumonia and sepsis caused by MRSA. The drug has been used in more than 250,000 patients, and its clinical benefit and safety have been proven over two decades. ABK currently shows promise for the application for the treatment of multidrug-resistant Gram-negative bacterial infections such as multidrug-resistant strains of P. aeruginosa and Acinetobacter baumannii because of its synergistic effect in combination with beta-lactams. Keywords: synergistic effect, Habekacin, MRSA, multidrug-resistant Gram-negative bacteria
format	article
author	Matsumoto T
author_facet	Matsumoto T
author_sort	Matsumoto T
title	Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
title_short	Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
title_full	Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
title_fullStr	Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
title_full_unstemmed	Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens
title_sort	arbekacin: another novel agent for treating infections due to methicillin-resistant staphylococcus aureus and multidrug-resistant gram-negative pathogens
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/a12cb9adffc44504ab76c3ce0a987e13
work_keys_str_mv	AT matsumotot arbekacinanothernovelagentfortreatinginfectionsduetomethicillinresistantstaphylococcusaureusandmultidrugresistantgramnegativepathogens
_version_	1718401449117876224

Arbekacin: another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

Ejemplares similares